Taken together, these findings suggest that METTL3 and YTHDF2 are both crucial for anti‐tumour immunity, and YTHDF2 probably functions as a downstream executed reader of the tumour‐killing effect of STM2457 treatment. This evidence concerns the gene METTL3 and neoplasm.